Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 4, 2001, Pages 342-349

  Cho, Hyun Soon ^a   Hyman, Bradley T ^a   Greenberg, Steven M ^a   Rebeck, G William ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyloid; Lipoprotein; Proteolysis; Receptor

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE DIAGNOSIS; RECEPTOR BINDING; VASCULAR AMYLOIDOSIS;

EID: 0035061891     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.4.342     Document Type: Article

References (47)

1. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
2. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
3. Apolipoprotein E: High-avidity binding to b-amyloid and increased frequence of type 4 allele in late-onset familial Alzheimer disease
4. Apolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy
5. Apolipoprotein E type 2 allele decreases the risk of late onset Alzheimer disease
6. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy
7. Association of apolipoprotein E e2 and vasculopathy in cerebral amyloid angiopathy
8. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
9. Progression of cerebral amyloid angiopathy. Accumulation of Aβ40 in already affected vessels
10. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein
11. The apolipoprotein E e2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage
12. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
13. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer disease
14. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage
15. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures
16. Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner
17. Amyloid-associated proteins al-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
18. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils
19. Acceleration of Alzheimer's disease fibril formation by apolipoprotein E in vitro
20. Apolipoprotein E: Structure-function relationships
21. Binding of human apolipoprotein E to βA4 peptide: Isoform specific effects and impications for late onset Alzheimer disease
22. β-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: Relevance to Alzheimer's disease
23. Kunitz protease inhibitor containing amyloid precursor protein immunoreactivity in Alzheimer's disease: A quantitative study
24. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution
25. Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: A possible role for apolipoprotein E in Alzheimer's disease
26. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity
27. Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
28. Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide β (1-40)
29. Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid β-peptide with the N-terminal, receptor binding domain of apolipoprotein E
30. Is Alzheimer's disease an apolipoprotein E amyloidosis?
31. Regional variation in the distribution of apolipoprotein E and Aβ in Alzheimer's disease
32. Inconstant apolipoprotein E (apoE)-like immunoreactivity in amyloid β protein deposits: Relationship with APOE genotype in aging brain and Alzheimer's disease
33. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease
34. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
35. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
36. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimers disease
37. Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly
38. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning
39. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mace but impaired clearance of axonal degeneration products following injury
40. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
41. Lipoprotein receptors: Signalling functions in the brain?
42. Direct binding of reelin to VLDL receptor and apoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation
43. Truncated apolipoprotein E (apoE) causes increased intracellular calcium and may mediate apoE neurotoxicity
44. The endocytic receptor, LRP, also mediates neuronal calcium signaling via NMDA receptors
45. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation
46. Isoform-specific effect of apolipoprotein E on cell survival and β-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures
47. Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases